miR-125a Restrains Cell Migration and Invasion by Targeting STAT3 in Gastric Cancer Cells [Retraction]

Yang L, Zhang S, Guo K, et al. *Onco Targets Ther.* 2019;12:205–215.

At the request of the authors, the Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article.

We were notified of potential image duplication in the published article. The issues relate to images shown in Figure 2B and 2C:

- Figure 2B 0 hour Panel MKN45 NC inhibitor appears to be duplicated with Figure 2B 0 hour Panel MKN45 miR-125a inhibitor.
- Figure 2C Panel MKN45 Blank control appears to be duplicated with Figure 2C Panel SGC7901 Blank control, which has been magnified.
- Figure 2C Panel MKN45 miR-125a mimic appears to be duplicated with Figure 2C Panel SGC7901 miR-125a mimic.
- Figure 2C Panel MKN45 NC inhibitor appears to be duplicated with Figure 2C Panel NCI-N87 NC inhibitor.

- Figure 2C Panel MKN45 si-STAT3 appears to be duplicated with Figure 2C Panel MKN45 si-HAS1.

The authors responded promptly to our queries but reported that some of the raw data for this study was missing and could only provide some of the required raw data. The editor determined that the findings of the study were no longer supported and the authors requested for the article to be retracted.

The authors wish to apologise for this error and may seek a separate publication of an updated manuscript in the future.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>